Corporate Events

Teijin Limited, Board Meeting, Jun 25, 2025. Agenda: To consider the disposal of treasury shares as "restricted stock" and "performance share units"; and.

Teijin Limited at its 159th Ordinary General Meeting of Shareholders held on June June 25, 2025 elected Toichi Maeda as Director and Tamie Minami and Yaeko Takeoka as Audit & Supervisory Committee Members. Audit & Supervisory Committee Members: Masanori Shimai, Tomoko Torii, Koich Tsuji, Tamie Minami and Yaeko Takeoka.

Teijin Limited announced that at its Ordinary General Meeting of Shareholders held on June 25, 2025, approved partial Amendments of the Articles of Incorporation.

Teijin Limited, Annual General Meeting, Jun 25, 2025, at 10:00 Tokyo Standard Time. Location: The Westin Osaka, 2nd Floor, Rose Room, 1-20 Oyodonaka 1-chome, Kita-ku, Osaka Japan Agenda: To consider partial amendments to the articles of incorporation; to consider election of six directors (excluding directors who are audit & supervisory committee members); to consider election of five directors who are audit & supervisory committee members; to consider election of one substitute director who is an audit & supervisory committee member; to consider determination of compensation amounts for directors (excluding directors who are audit & supervisory committee members); to consider determination of compensation amounts for directors who are audit & supervisory committee members; to consider determination of the restricted stock plan and performance share units plan for directors (excluding outside directors and directors who are audit & supervisory committee members).

Nakashima Holdings Co., Ltd. agreed to acquire remaining 50% stake in Teijin Nakashima Medical Co., Ltd. from Teijin Limited (TSE:3401) on April 25, 2025. Upon completion, Nakashima Holdings Co., Ltd. will own 100% stake in Teijin Nakashima Medical Co., Ltd. The expected completion of the transaction is June 16, 2025. Upon completion of the Transaction Teijin Nakashima Medical will cease to be a consolidated subsidiary of Teijin and become a wholly owned subsidiary of Nakashima Holdings. At that time, it will begin a new chapter under the new name NAKASHIMA HEALTHFORCE CO., LTD.

Teijin Limited, Board Meeting, May 12, 2025. Agenda: To submit the proposal for "Partial Amendments to the Articles of Incorporation" to the 159th Annual General Meeting of Shareholders to be held on June 25, 2025.

Asahi Group Foods, Ltd. signed a share transfer agreement to acquire Meguro Institute Co., Ltd. from Teijin Limited (TSE:3401) on April 25, 2025. On the date of the closing of the transaction, Meguro Institute Co., Ltd. will be renamed as Asahi Meguro Laboratory and will start its business. The expected completion of the transaction is May 1, 2025.

Teijin Limited, 2025 Earnings Call, May 12, 2025

Teijin Limited, Board Meeting, Mar 31, 2025. Agenda: To consider to transfer all of its shares in Teijin Automotive Technologies NA Holdings Corp.; to consider the reason for the share transfer; to consider the outline of the consolidated subsidiary; to consider the outline of transferee; to consider the consider the share transfer; to consider the schedule; and to consider the outlook.

Fibers & Products Converting Business Briefing Session

Teijin Limited announced that they will report fiscal year 2025 results on May 12, 2025

Teijin Limited expected to report Fiscal Year 2025 results on May 9, 2025. This event was calculated by S&P Global (Created on February 5, 2025).

Teijin Limited announced that at the Ordinary General Meeting of Shareholders scheduled to be held in June 2025, proposed as amendments to the Articles of Incorporation.

Teijin Limited, Q3 2025 Earnings Call, Feb 06, 2025

Teijin Limited Presents at 2024 Cell & Gene Meeting on the Mesa, Oct-07-2024 . Venue: Arizona Biltmore, FLW, 2400 E Missouri Ave, Phoenix , Arizona, United States.

Teijin Limited announced that they will report Q3, 2025 results on Feb 06, 2025

Circularise B.V. announced that it will raise a round of funding from new investor Teijin Limited on December 3, 2024.

Healthcare Business Briefing Session

Teijin Limited announced dividend of JPY 25.00 per share for the second quarter ended September 30, 2024 against JPY 15.00 per share a year ago. Scheduled date for dividends payment is December 2, 2024. The company provided dividend guidance for the fourth quarter ending March 31, 2025. For the fourth quarter, the company expects to pay dividend of JPY 25.00 per share against JPY 15.00 per share a year ago.

Teijin Limited, Board Meeting, Nov 07, 2024. Agenda: To distribute dividends of surplus to shareholders (an interim dividend), with a record date of September 30, 2024, and to revise the yearend dividend forecast announced on May 13, 2024.

Teijin Limited, ¥ 25.0, Cash Dividend, Mar-28-2025

Teijin Limited expected to report Q3 2025 results on February 6, 2025. This event was calculated by S&P Global (Created on November 7, 2024).

Teijin Limited revised consolidated earnings guidance for the year ending March 31, 2025. For the year, the company expects revenue of JPY 1,010,000 million compared to previous guidance of JPY 1,010,000 a year ago. Operating loss of JPY 80,000 million compared to previous guidance of JPY 19,000 million. Profit attributable to owners of parent of JPY 25,000 million. Basic earnings per share of JPY 129.78.

Teijin Limited and Hilleman Laboratories, announced the signing of a Memorandum of Understanding, for the establishment of a strategic international business partnership. The goal of this partnership is to promote the expansion in contract development and manufacturing organization (CDMO) business in the field of cell and gene therapy. Under this partnership, Teijin and Hilleman Laboratories will leverage their individual strengths to foster greater synergy for the development and manufacturing of cell and gene therapy products, and mutually advance CDMO business activities of respective parties. The partnership was formed to strengthen support for Japanese customers aiming to expand into the Asia-Pacific region and to attract overseas customers from Singapore and surrounding areas to the Japanese market. Further, Teijin and Hilleman Laboratories share a vision for building a support system in Singapore for the development and manufacturing of cell and gene therapies. In November 2023, Hilleman Laboratories launched its newest facility, a 30,000 square foot current Good Manufacturing Practice (cGMP) pilot-scale plant. Building upon this, Teijin will support Hilleman Laboratories in the establishment of a cell processing center in Singapore for cell and gene therapy. Teijin's accumulated knowledge and experience in this field will be shared with Hilleman Laboratories. Teijin group will invest in facilities and human resources to meet customer needs, with a goal of generating JPY 20 billion in regenerative medicine sales by Fiscal Year 2030. The partnership with Hilleman Laboratories will help achieve this goal. Demand for CDMO services in cell and gene therapies, including regenerative medicines, is rising due to heightened technical levels in manufacturing and greater specialization in manufacturing and development functions. The fast-growing regenerative medicine market in Japan is forecast to exceed JPY 850 billion in 2030. This trend is expected to result in a greater number of regenerative medicine products that originate outside Japan. For this reason, it is vital to create a system that connects development demand within and outside Japan.

Teijin Limited, Q2 2025 Earnings Call, Nov 07, 2024

Teijin Limited announced that they will report Q2, 2025 results on Nov 07, 2024

Teijin Limited provided dividend guidance for the fiscal first half of and full year of fiscal year ending March 31, 2025. For the first half, the company expects to pay dividend of JPY 15.00 per share against JPY 15.00 per share a year ago. For the year, the company expects to pay dividend of JPY 15.00 per share against JPY 15.00 per share a year ago.

Teijin Limited revised consolidated earnings guidance for the fiscal full year ending March 31, 2025. For the year, the company expects net revenue to be JPY 1,010,000 million and operating income to be JPY 19,000 million.